伴平滑肌瘤样间质的肾细胞癌存在TSC1、TSC2、MTOR和/或ELOC体细胞突变:18例散发性肿瘤的临床病理和分子特征支持其为独立实体
该研究分析了23例伴平滑肌间质的散发性肾细胞癌,分为RCCLMS(18例)和透明细胞肾细胞癌(5例)。RCCLMS均存在TSC1、TSC2、MTOR和/或ELOC的反复突变,且VHL基因完整,随访患者均无进展。结果支持RCCLMS是不同于透明细胞肾细胞癌和透明细胞乳头状肾细胞癌的独立实体,且为结节性硬化症相关肿瘤的散发性对应。
要点
- RCCLMS定义为具有平滑肌间质、弥漫CK7表达且形态类似TSC相关肾细胞癌的肿瘤。
- 所有检测的RCCLMS均携带TSC1、TSC2、MTOR和/或ELOC突变,提示MTOR复合物过度激活。
- RCCLMS均为pT1期,随访患者均无病生存,但样本量有限。
核心结论
- RCCLMS存在TSC1/TSC2、MTOR和/或ELOC的反复突变,支持其为独立于透明细胞肾细胞癌和透明细胞乳头状肾细胞癌的新亚型。
- RCCLMS可能是结节性硬化症患者中形态相同肿瘤的散发性对应。
研究设计与样本
- 回顾性分析23例伴平滑肌间质的散发性肾细胞癌,分为RCCLMS组(18例)和透明细胞肾细胞癌对照组(5例)。
- 使用170基因实体瘤 panel 对14例RCCLMS和5例透明细胞肾细胞癌测序,4例疑似8号染色体单体的RCCLMS进一步用479基因 panel 检测ELOC。
主要发现
- RCCLMS患者平均年龄52岁(范围33-69),男女比1:2,所有肿瘤单发,82%呈棕红色、界限清楚、实性,平均大小2.3 cm(范围1.1-4.5)。
- 组织学上100%见由透明至轻度嗜酸性胞质细胞衬覆的细长分支管状结节,间以平滑肌间质;50%见双相塌陷腺泡,39%见局灶乳头状结构,39%见瘤周淋巴聚集,33%见含铁血黄素巨噬细胞。
- 有分期信息的11例RCCLMS均为pT1;78%为WHO/ISUP 2级,22%为3级;免疫表型100%弥漫表达CK7、CAM5.2和CD10。
- 随访10例均存活且无进展,平均随访25.2个月(范围1-58),中位随访25个月。
- 所有RCCLMS均检出TSC1(4例)、TSC2(4例)、MTOR(6例)和/或ELOC(2例)突变;5例对照透明细胞肾细胞癌有VHL原发改变,而14例检测的RCCLMS VHL基因完整。
关键数值与推荐
- RCCLMS诊断基于与3例结节性硬化症患者5个指示肿瘤的形态学比较及弥漫CK7表达。
- RCCLMS肿瘤平均大小2.3 cm(范围1.1-4.5),82%呈棕红色、界限清楚、实性。
- 100%RCCLMS表达CK7、CAM5.2和CD10;78%为WHO/ISUP 2级,22%为3级。
临床怎么用
- 病理诊断RCCLMS需结合形态学(管状结构、平滑肌间质)和免疫组化(弥漫CK7、CAM5.2、CD10),并与透明细胞肾细胞癌鉴别。
- 分子检测发现TSC1/TSC2、MTOR或ELOC突变可支持RCCLMS诊断,并提示MTOR通路激活。
局限性
- 样本量较小(18例RCCLMS),随访数据有限(仅10例)。
- 为回顾性研究,分子检测仅在部分病例中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal cell carcinoma with (angio) leiomyomatous stroma (RCCLMS) is included as a provisional entity in the 2016 World Health Organization (WHO) classification of renal epithelial neoplasia; however, debate remains whether it represents a distinct entity or a heterogenous group of renal cell carcinomas (RCCs) with overlapping morphology. Also, its relationship to similar tumors occurring in the setting of tuberous sclerosis complex (TSC) is not fully addressed. We analyzed the clinicopathologic, immunohistochemical, and molecular characteristics of 23 sporadic RCCs associated with smooth muscle stroma and classified them into 2 groups, independent of molecular results: (1) RCCLMS (n=18) and (2) clear cell renal cell carcinoma (CCRCC) (n=5). The classification of a case as "RCCLMS" was based on morphologic comparison with 5 "index" RCCs from 3 patients with TSC showing similar features and the presence of diffuse CK7 expression. To investigate mutational and copy number alterations, a 170-gene solid tumor panel was utilized to sequence 14 RCCLMSs and control of 5 CCRCCs. Also, 4 RCCLMSs, suspicious for chromosome 8 monosomy, were further evaluated by a broader 479 gene sequencing panel that included ELOC (also referred to as TCEB1). Clinical information and follow-up data were obtained from electronic medical records. The mean age of patients with RCCLMS was 52 years (range, 33 to 69) with male:female ratio of 1:2. Macroscopically, all tumors were solitary and predominantly (82%) tan/red, circumscribed, and solid. The average tumor size was 2.3 cm (range, 1.1 to 4.5). Microscopically, the distinctive feature included tumor nodules of elongated and frequently branching tubules lined by cells with voluminous clear to mildly eosinophilic cytoplasm (100%), separated by focal to prominent smooth muscle stroma. Additional frequently identified features included: biphasic pattern of collapsed acini surrounding tubules with voluminous cytoplasm (50%), focal papillary architecture (39%), peritumoral lymphoid aggregates (39%), and hemosiderin-laden macrophages (33%). All 11 (100%) RCCLMSs with available staging information were pT1; 78% were WHO/International Society of Urologic Pathology (ISUP) grade 2 and 22% grade 3. Immunophenotypically, RCCLMSs were characterized by diffuse CK7, CAM5.2 and CD10 reactivity (100%). All patients with available follow-up (n=10) were alive and without disease progression after a mean and median follow-up of 25.2 (range: 1 to 58) and 25 months, respectively. The molecular results showed recurrent mutations in all RCCLMS: TSC1 (4), TSC2 (4), MTOR (6), and/or ELOC (2). Five control CCRCCs demonstrated primary alterations in VHL gene, while all 14 RCCLMS cases tested had intact VHL gene. Of 2 RCCLMSs with confirmed monosomy 8, 1 showed a hotspot ELOC mutation without TSC/MTOR mutations, and 1 showed a previously undescribed 3-bp in-frame ELOC deletion, along with a truncating TSC1 mutation. In conclusion, RCCLMS, as defined herein, harbors recurrent mutations of TSC1/TSC2, MTOR, and/or ELOC, consistent with hyperactive MTOR complex. Our findings argue that these tumors represent the sporadic counterpart to morphologically identical tumors occurring in TSC patients. Finally, the data support that RCCLMS is a novel subtype of RCC with unique morphologic, immunohistochemical, and molecular characteristics that is distinct from CCRCC and clear cell-papillary RCC.
引用
- Shah RB, Stohr BA, Tu ZJ, et al. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020. PMID: 31850909. doi:10.1097/PAS.0000000000001422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。